News + Filings Transactions Holdings
All 13F 13D/G Other
|
ORBIMED ADVISORS LLC
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/04/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.7% stake in Synlogic, Inc. |
10/02/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.5% stake in PMV Pharmaceuticals, Inc. |
08/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 5.9% stake in Galecto, Inc. |
08/11/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8% stake in Gracell Biotechnologies Inc. |
08/03/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 56.7% stake in Xtant Medical Holdings, Inc. |
08/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8.3% stake in Galecto, Inc. |
07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 9.6% stake in Galecto, Inc. |
06/29/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 14.7% stake in Passage BIO, Inc. |
06/29/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 15.5% stake in Adicet Bio, Inc. |
05/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 28.6% stake in Prelude Therapeutics Incorporated |
05/17/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 6.7% stake in SpringWorks Therapeutics, Inc. |
05/16/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.6% stake in Fusion Pharmaceuticals Inc. |
05/16/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.8% stake in Verona Pharma plc |
05/08/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 16.2% stake in Kinnate Biopharma Inc. |
05/05/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 67.1% stake in Xtant Medical Holdings, Inc. |
05/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.1% stake in Kinnate Biopharma Inc. |
04/21/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 5.4% stake in CalciMedica, Inc. |
03/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 0% stake in 89bio, Inc. |
03/22/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 18.9% stake in CalciMedica, Inc. |
03/14/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 39.6% stake in Theseus Pharmaceuticals, Inc. |
02/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 10.6% stake in Kinnate Biopharma Inc. |
01/26/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 3.2% stake in 89bio, Inc. |
01/05/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8% stake in SpringWorks Therapeutics, Inc. |
01/03/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 12.8% stake in Disc Medicine, Inc. |
12/28/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/27/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.5% stake in ORIC Pharmaceuticals, Inc. |
12/27/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 5.6% stake in Verona Pharma plc |
11/30/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 8.3% stake in ARS Pharmaceuticals, Inc. |
11/29/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 16.3% stake in scPharmaceuticals Inc. |
11/25/2022 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 1.1% stake in Tricida, Inc. |
|
|
|